Marion E. Morrison

729 total citations
16 papers, 526 citations indexed

About

Marion E. Morrison is a scholar working on Epidemiology, Oncology and Rheumatology. According to data from OpenAlex, Marion E. Morrison has authored 16 papers receiving a total of 526 indexed citations (citations by other indexed papers that have themselves been cited), including 7 papers in Epidemiology, 6 papers in Oncology and 4 papers in Rheumatology. Recurrent topics in Marion E. Morrison's work include Virus-based gene therapy research (4 papers), Cytomegalovirus and herpesvirus research (4 papers) and Drug Transport and Resistance Mechanisms (3 papers). Marion E. Morrison is often cited by papers focused on Virus-based gene therapy research (4 papers), Cytomegalovirus and herpesvirus research (4 papers) and Drug Transport and Resistance Mechanisms (3 papers). Marion E. Morrison collaborates with scholars based in United States, United Kingdom and South Korea. Marion E. Morrison's co-authors include Thomas M. Brundage, Greg Chittick, W. Garrett Nichols, Roy F. Chemaly, Herve Momméja-Marin, Timothy K. Tippin, Genovefa A. Papanicolaou, Francisco M. Marty, Michael Boeckh and Drew J. Winston and has published in prestigious journals such as Transplantation, Thrombosis and Haemostasis and British Journal of Clinical Pharmacology.

In The Last Decade

Marion E. Morrison

16 papers receiving 501 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Marion E. Morrison United States	9	356	167	143	134	122	16	526
Corinne Loeuillet France	12	168 0.5×	166 1.0×	84 0.6×	33 0.2×	100 0.8×	24	516
Laëtitia Carthagéna France	10	145 0.4×	137 0.8×	142 1.0×	33 0.2×	115 0.9×	12	499
Manoj Kumar Tripathy France	12	228 0.6×	184 1.1×	313 2.2×	37 0.3×	208 1.7×	20	663
E Elfassi France	12	468 1.3×	113 0.7×	96 0.7×	59 0.4×	84 0.7×	16	532
Marlene Chernow United States	8	252 0.7×	71 0.4×	128 0.9×	38 0.3×	102 0.8×	9	445
Jose A. Garcia-Rivera United States	11	161 0.5×	178 1.1×	106 0.7×	32 0.2×	139 1.1×	18	426
Sarah Meisner United Kingdom	7	196 0.6×	88 0.5×	49 0.3×	30 0.2×	252 2.1×	11	572
Hugh C. Welles United States	9	104 0.3×	113 0.7×	109 0.8×	79 0.6×	126 1.0×	14	339
J L Hurwitz United States	20	278 0.8×	281 1.7×	224 1.6×	54 0.4×	137 1.1×	41	970

Countries citing papers authored by Marion E. Morrison

Since Specialization

Citations

This map shows the geographic impact of Marion E. Morrison's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Marion E. Morrison with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Marion E. Morrison more than expected).

Fields of papers citing papers by Marion E. Morrison

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Marion E. Morrison. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Marion E. Morrison. The network helps show where Marion E. Morrison may publish in the future.

Co-authorship network of co-authors of Marion E. Morrison

This figure shows the co-authorship network connecting the top 25 collaborators of Marion E. Morrison. A scholar is included among the top collaborators of Marion E. Morrison based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Marion E. Morrison. Marion E. Morrison is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

16 of 16 papers shown

Arumugham, Thangam, et al.. (2025). Effect of Severe Renal Impairment on Dordaviprone (ONC201) Pharmacokinetics. Drugs in R&D. 25(3). 253–261. 1 indexed citations

Arumugham, Thangam, et al.. (2025). A phase 1, randomized, crossover trial to assess the effect of itraconazole on the pharmacokinetics of dordaviprone in healthy adults. British Journal of Clinical Pharmacology. 91(9). 2605–2612. 3 indexed citations

Arumugham, Thangam, et al.. (2025). A Phase 1 Randomized Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of Single Escalating Oral Doses of Dordaviprone and the Effects of Food on the Bioavailability of Dordaviprone in Healthy Adult Subjects. Clinical Pharmacology in Drug Development. 14(5). 382–390. 4 indexed citations

Teffera, Yohannes, et al.. (2025). A Phase 1 Study to Evaluate the Absorption, Metabolism, and Disposition of Dordaviprone in Healthy Adult Participants. Clinical Pharmacology in Drug Development. 14(7). 549–556. 2 indexed citations

Arumugham, Thangam, et al.. (2024). Relative Bioavailability of Dordaviprone (ONC201) is Not Affected by Co‐Administration of the Proton‐Pump Inhibitor Rabeprazole. The Journal of Clinical Pharmacology. 65(4). 520–526. 2 indexed citations

Lasky, Joseph A., Jyotsna Fuloria, Marion E. Morrison, et al.. (2020). Design and Rationale of a Randomized, Double-Blind, Placebo-Controlled, Phase 2/3 Study Evaluating Dociparstat in Acute Lung Injury Associated with Severe COVID-19. Advances in Therapy. 38(1). 782–791. 13 indexed citations

Marty, Francisco M., Drew J. Winston, Roy F. Chemaly, et al.. (2018). A Randomized, Double-Blind, Placebo-Controlled Phase 3 Trial of Oral Brincidofovir for Cytomegalovirus Prophylaxis in Allogeneic Hematopoietic Cell Transplantation. Biology of Blood and Marrow Transplantation. 25(2). 369–381. 157 indexed citations

Naderer, Odin, et al.. (2018). 1421. IV Brincidofovir (BCV): Pharmacokinetics (PK) and Safety of Multiple Ascending Doses (MAD) in Healthy Subjects. Open Forum Infectious Diseases. 5(suppl_1). S438–S439. 2 indexed citations

Chittick, Greg, Marion E. Morrison, Thomas M. Brundage, & W. Garrett Nichols. (2017). Short-term clinical safety profile of brincidofovir: A favorable benefit–risk proposition in the treatment of smallpox. Antiviral Research. 143. 269–277. 96 indexed citations

10.

Wire, Mary Beth, et al.. (2017). Pharmacokinetics (PK) and Safety of Intravenous (IV) Brincidofovir (BCV) in Healthy Adult Subjects. Open Forum Infectious Diseases. 4(suppl_1). S311–S311. 8 indexed citations

11.

Grimley, Michael, Roy F. Chemaly, Janet A. Englund, et al.. (2017). Brincidofovir for Asymptomatic Adenovirus Viremia in Pediatric and Adult Allogeneic Hematopoietic Cell Transplant Recipients: A Randomized Placebo-Controlled Phase II Trial. Biology of Blood and Marrow Transplantation. 23(3). 512–521. 118 indexed citations

12.

Tippin, Timothy K., Marion E. Morrison, Thomas M. Brundage, & Herve Momméja-Marin. (2016). Brincidofovir Is Not a Substrate for the Human Organic Anion Transporter 1: A Mechanistic Explanation for the Lack of Nephrotoxicity Observed in Clinical Studies. Therapeutic Drug Monitoring. 38(6). 777–786. 58 indexed citations

13.

Marty, Francisco M., Drew J. Winston, Roy F. Chemaly, et al.. (2016). Brincidofovir for Prevention of Cytomegalovirus (CMV) after Allogeneic Hematopoietic Cell Transplantation (HCT) in CMV-Seropositive Patients: A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Phase 3 Trial. Biology of Blood and Marrow Transplantation. 22(3). S23–S23. 29 indexed citations

14.

Morrison, Marion E., et al.. (2014). Switch From Existing Antivirals to Brincidofovir Leads to Improving Renal Function.. Transplantation. 98. 106–106. 2 indexed citations

15.

Hawkins, J. Ross, Marion E. Morrison, Malcolm Hawkins, et al.. (2006). Establishment of the 1st International Genetic Reference Panel for Factor V Leiden, human gDNA. Thrombosis and Haemostasis. 96(8). 215–219. 10 indexed citations

16.

Morrison, Marion E., et al.. (1985). Penicillamine in ankylosing spondylitis: a double blind placebo controlled trial.. PubMed. 12(4). 735–7. 21 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact